Yuichiro Ohe

41.6k total citations · 9 hit papers
561 papers, 21.9k citations indexed

About

Yuichiro Ohe is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Yuichiro Ohe has authored 561 papers receiving a total of 21.9k indexed citations (citations by other indexed papers that have themselves been cited), including 400 papers in Oncology, 368 papers in Pulmonary and Respiratory Medicine and 120 papers in Molecular Biology. Recurrent topics in Yuichiro Ohe's work include Lung Cancer Treatments and Mutations (324 papers), Lung Cancer Research Studies (175 papers) and Lung Cancer Diagnosis and Treatment (106 papers). Yuichiro Ohe is often cited by papers focused on Lung Cancer Treatments and Mutations (324 papers), Lung Cancer Research Studies (175 papers) and Lung Cancer Diagnosis and Treatment (106 papers). Yuichiro Ohe collaborates with scholars based in Japan, United States and United Kingdom. Yuichiro Ohe's co-authors include Nagahiro Saijo, James Chih‐Hsin Yang, Yutaka Nishiwaki, Tomohide Tamura, Masahiro Fukuoka, Yukito Ichinose, Haiyi Jiang, Noboru Yamamoto, Tony Mok and Emma Duffield and has published in prestigious journals such as New England Journal of Medicine, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Yuichiro Ohe

539 papers receiving 21.4k citations

Hit Papers

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocar... 2005 2026 2012 2019 2009 2015 2005 2006 2013 2.0k 4.0k 6.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
    2009 6.4k citations Nagahiro Saijo, Yuichiro Ohe et al. profile →
  2. AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
    2015 1.6k citations Yuichiro Ohe, Suresh S. Ramalingam et al. profile →
  3. Epidermal Growth Factor Receptor Gene Mutations and Increased Copy Numbers Predict Gefitinib Sensitivity in Patients With Recurrent Non–Small-Cell Lung Cancer
    2005 606 citations Toshimi Takano, Yuichiro Ohe et al. profile →
  4. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan
    2006 515 citations Yuichiro Ohe, Kaoru Kubota et al. profile →
  5. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study
    2013 449 citations Takashi Seto, Makoto Nishio et al. profile →
  6. Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer
    2017 380 citations Suresh S. Ramalingam, Yuichiro Ohe et al. profile →
  7. TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer
    2020 303 citations Kōichi Goto, Yuichiro Ohe et al. profile →
  8. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial
    2022 244 citations Yuichiro Ohe et al. profile →
  9. Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer
    2023 130 citations Juliann Chmielecki, Jhanelle E. Gray et al. Nature Communications profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yuichiro Ohe Japan 61 14.9k 14.4k 5.9k 3.9k 1.6k 561 21.9k
D. Ross Camidge United States 77 16.9k 1.1× 15.0k 1.0× 8.6k 1.5× 4.6k 1.2× 1.4k 0.9× 539 24.2k
Lucio Crinò Italy 67 13.4k 0.9× 13.5k 0.9× 5.5k 0.9× 3.3k 0.8× 1.1k 0.7× 372 19.4k
David Planchard France 58 10.0k 0.7× 11.0k 0.8× 4.6k 0.8× 3.4k 0.9× 1.3k 0.8× 431 16.5k
Benjamin Solomon Australia 61 14.1k 0.9× 12.7k 0.9× 6.7k 1.1× 4.3k 1.1× 880 0.6× 415 20.8k
Yuichi Ishikawa Japan 53 9.7k 0.7× 8.8k 0.6× 7.5k 1.3× 3.8k 1.0× 2.2k 1.4× 265 17.9k
Joachim von Pawel Germany 64 16.9k 1.1× 17.7k 1.2× 7.2k 1.2× 3.2k 0.8× 2.3k 1.4× 254 25.0k
Benjamin Besse France 64 10.4k 0.7× 12.2k 0.9× 5.6k 1.0× 3.8k 1.0× 1.2k 0.8× 708 18.8k
Nobuyuki Yamamoto Japan 58 12.5k 0.8× 11.6k 0.8× 4.0k 0.7× 2.5k 0.6× 1.2k 0.8× 574 17.3k
Masahiro Fukuoka Japan 55 16.7k 1.1× 15.2k 1.1× 6.1k 1.0× 3.3k 0.8× 2.0k 1.3× 266 22.5k
Julien Mazières France 59 9.7k 0.6× 10.7k 0.7× 5.7k 1.0× 3.0k 0.8× 1.0k 0.7× 441 17.0k

Countries citing papers authored by Yuichiro Ohe

Since Specialization
Citations

This map shows the geographic impact of Yuichiro Ohe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuichiro Ohe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuichiro Ohe more than expected).

Fields of papers citing papers by Yuichiro Ohe

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuichiro Ohe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuichiro Ohe. The network helps show where Yuichiro Ohe may publish in the future.

Co-authorship network of co-authors of Yuichiro Ohe

This figure shows the co-authorship network connecting the top 25 collaborators of Yuichiro Ohe. A scholar is included among the top collaborators of Yuichiro Ohe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuichiro Ohe. Yuichiro Ohe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Matsumoto, Yoshihisa, Shigeki Umemura, Daisuke Fujisawa, et al.. (2024). Nurse‐Led Screening‐Triggered Early Specialized Palliative Care Program for Patients With Advanced Lung Cancer: A Multicenter Randomized Controlled Trial. Cancer Medicine. 13(22). e70325–e70325. 1 indexed citations
2.
Matsumoto, Yuji, Jumpei Kashima, Tatsuya Imabayashi, et al.. (2023). Concordance between cryobiopsy and forceps biopsy specimens in assessment of immunohistochemistry staining for non-small cell lung carcinoma. Translational Lung Cancer Research. 12(6). 1245–1255. 4 indexed citations
3.
Motoi, Noriko, Masaya Yotsukura, Yukihiro Yoshida, et al.. (2023). Clinicopathological characteristics and molecular analysis of lung cancer associated with ciliated muconodular papillary tumor/bronchiolar adenoma. Pathology International. 73(5). 188–197. 2 indexed citations
4.
Shimokawa, Tsuneo, Hiroaki Okamoto, Ryunosuke Machida, et al.. (2023). Carboplatin and irinotecan (CI) vs. carboplatin and etoposide (CE) for the treatment of extended-stage small-cell lung cancer in an elderly population: A phase II/III randomized control trial. Lung Cancer. 181. 107195–107195. 4 indexed citations
5.
Yoshida, Tatsuya, Shigehiro Yagishita, Yuji Matsumoto, et al.. (2023). Clinical Characteristics and Pharmacokinetics Change of Long-Term Responders to Antiprogrammed Cell Death Protein 1 Inhibitor Among Patients With Advanced NSCLC. JTO Clinical and Research Reports. 4(4). 100474–100474. 3 indexed citations
6.
Yagishita, Shigehiro, Yoshiharu Hayashi, Yuki Takeyasu, et al.. (2023). Impact of ramucirumab pharmacokinetics in combination with docetaxel on the efficacy and survival in patients with advanced non-small cell lung cancer. Lung Cancer. 178. 247–253. 1 indexed citations
7.
Chmielecki, Juliann, Jhanelle E. Gray, Ying Cheng, et al.. (2023). Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer. Nature Communications. 14(1). 1070–1070. 130 indexed citations breakdown →
8.
9.
Yoshida, Tatsuya, Toru Kumagai, Ryo Toyozawa, et al.. (2023). Brigatinib in Japanese patients with ALK‐positive non‐small‐cell lung cancer: Final results of the phase 2 J‐ALTA trial. Cancer Science. 114(9). 3698–3707. 7 indexed citations
10.
Kashima, Jumpei, Taiki Hashimoto, Akihiko Yoshida, et al.. (2022). Insulinoma-associated-1 (INSM1) expression in thymic squamous cell carcinoma. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 481(6). 893–901. 6 indexed citations
11.
Naito, Tomoyuki, Hibiki Udagawa, Kōichi Goto, et al.. (2022). Nivolumab‐induced radiation recall pneumonitis in non‐small‐cell lung cancer patients with thoracic radiation therapy. Cancer Science. 114(2). 630–639. 6 indexed citations
12.
Tanimoto, Azusa, Shingo Matsumoto, Shinji Takeuchi, et al.. (2020). Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK -Rearranged/ TP53 -Mutant NSCLC via Noxa Expression. Clinical Cancer Research. 27(5). 1410–1420. 38 indexed citations
13.
14.
Murakami, Shuji, Ryota Shibaki, Yuji Matsumoto, et al.. (2020). Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non‐small cell lung cancer treated with anti‐PD‐1 antibody. Thoracic Cancer. 11(12). 3585–3595. 36 indexed citations
15.
Ito, Kimihiro, Makoto Nishio, Masanori Kato, et al.. (2019). TAS-121, A Selective Mutant EGFR Inhibitor, Shows Activity Against Tumors Expressing Various EGFR Mutations Including T790M and Uncommon Mutations G719X. Molecular Cancer Therapeutics. 18(5). 920–928. 10 indexed citations
16.
Tanaka, Midori, Hidehito Horinouchi, Yasushi Goto, et al.. (2018). Reduction in nephrotoxicities using short hydration for chemotherapy containing cisplatin: a consecutive analysis of 467 patients with thoracic malignancies. ESMO Open. 3(4). e000342–e000342. 10 indexed citations
17.
Shinno, Yuki, Yasushi Goto, Sho Watanabe, et al.. (2018). Evaluation of time to failure of strategy as an alternative surrogate endpoint in patients with lung cancer with EGFR mutations. ESMO Open. 3(7). e000399–e000399. 5 indexed citations
18.
Yoshida, Tatsuya, Genichiro Ishii, Kōichi Goto, et al.. (2014). Podoplanin-Positive Cancer-Associated Fibroblasts in the Tumor Microenvironment Induce Primary Resistance to EGFR-TKIs in Lung Adenocarcinoma with EGFR Mutation. Clinical Cancer Research. 21(3). 642–651. 102 indexed citations
19.
Okano, Tetsuya, Tadashi Kondo, Kiyonaga Fujii, et al.. (2007). Proteomic Signature Corresponding to the Response to Gefitinib (Iressa, ZD1839), an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma. Clinical Cancer Research. 13(3). 799–805. 49 indexed citations
20.
Ohe, Yuichiro, Kazuhiko Nakagawa, Yasuhiro Fujiwara, et al.. (1989). In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines.. PubMed. 49(15). 4098–102. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by D. Ross Camidge Breakdown of academic impact, for papers by Lucio Crinò Breakdown of academic impact, for papers by David Planchard Breakdown of academic impact, for papers by Benjamin Solomon Breakdown of academic impact, for papers by Yuichi Ishikawa Breakdown of academic impact, for papers by Joachim von Pawel Breakdown of academic impact, for papers by Benjamin Besse Breakdown of academic impact, for papers by Nobuyuki Yamamoto Breakdown of academic impact, for papers by Masahiro Fukuoka Breakdown of academic impact, for papers by Julien Mazières
Rankless by CCL
2026